Literature DB >> 7556305

Radiopharmaceuticals 1994. Nil desperandum. European Association of Nuclear Medicine Committees on Radiopharmaceuticals and Positron Emission Tomography.

P H Cox1, G J Meyer.   

Abstract

On the basis of the discussions at a symposium held in Düsseldorf and attended by representatives of various interested bodies, European legislation as it affects radiopharmaceuticals is reviewed. Due consideration is given to the new, centralised and decentralised, registration procedures, effective since 1 January 1995. The dossier required to support an application for marketing authorisation is discussed, separate consideration being given to single-photon emitters, therapeutic radio-nuclides and positron-emitting radiopharmaceuticals. The role of the European Pharmacopoiea is also considered. It is concluded that the new, modified procedures for the registration of medicinal products in the European Union may actually inhibit free availability of radio-pharmaceuticals within the Community, and that there is a strong case for modification of the European Directives so that radiopharmaceuticals are placed in a separate category to therapeutic drugs, with less stringent registration requirements.

Mesh:

Substances:

Year:  1995        PMID: 7556305     DOI: 10.1007/bf00817284

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  7 in total

1.  Challenges for nuclear medicine in the 1990s.

Authors:  P J Ell
Journal:  Nucl Med Commun       Date:  1992-02       Impact factor: 1.690

2.  Report and recommendations on the requirements for postgraduate training in radiopharmacy and radiopharmaceutical chemistry 1989. European Association of Nuclear Medicine Task Group on Radiopharmaceuticals.

Authors: 
Journal:  Eur J Nucl Med       Date:  1990

3.  Dosimetric consequences of interstitial extravasation following i.v. administration of a radiopharmaceutical.

Authors:  B Shapiro; M Pillay; P H Cox
Journal:  Eur J Nucl Med       Date:  1987

4.  Radiopharmaceuticals and the single European market.

Authors:  C D Hewat; J Ogle; C Fallais
Journal:  Eur J Nucl Med       Date:  1993-08

5.  EEC directives and guidelines applicable to radiopharmaceuticals--1993. Status quo with particular emphasis on the registration of radiopharmaceuticals which were on the market prior to January 1992.

Authors:  P H Cox
Journal:  Eur J Nucl Med       Date:  1993-08

6.  European Community legislation affecting radiopharmaceuticals: cold fusion or illusion?

Authors:  P H Cox
Journal:  J Nucl Biol Med       Date:  1994-09

7.  Criteria for the use of monoclonal antibodies, legislation and ethical considerations.

Authors:  P H Cox
Journal:  Nucl Med Commun       Date:  1993-08       Impact factor: 1.690

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.